Biogen's stock plummet shows the 'investment model in drug development is all wrong,' says former Aetna CEO – CNBC
Former Aetna Chairman and CEO Mark Bertolini says investors currently are trading “on a basis that says, ‘does this drug work today? Did this trial pass today?
Source: Investment New Feed